Abstract: The present invention discloses a process for the preparation of a hydroxymethylthiazole compound having formula 3: The process of the invention comprises reacting a halomethyl thiazole having the formula: ##STR1## with water, at an elevated temperature. Optionally, the reaction can be carried out in the presence of a base, such as sodium carbonate, which can react with any acid formed. In the process of the invention, X is a halogen atom; and R.sup.6 is selected from the group consisting of hydrogen, and halogen atoms. The invention also contemplates the preparation of acid addition salts of the hydroxymethylthiazole, compound 3.
Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.
Type:
Grant
Filed:
March 13, 1995
Date of Patent:
September 7, 1999
Assignee:
Abbott Laboratories
Inventors:
Laman A. Al-Razzak, Kennan C. Marsh, Dilip Kaul, Lourdes P. Manning
Abstract: The present invention discloses a process for the preparation of a compound having formula 4: ##STR1## The process comprises the step of reacting an enolate having the formula: ##STR2## with a Grignard reagent. The enolate salt is formed in situ from the reaction of a protected ester wherein M is an alkali metal. R.sub.6 and R.sub.7 are each hydrogen or are independently selected from ##STR3## wherein R.sub.a and R.sub.b are independently selected from hydrogen, lower alkyl and phenyl and R.sub.c, R.sub.d and R.sub.e are independently selected from hydrogen, lower alkyl, trifluoromethyl, alkoxy, halo and phenyl; and ##STR4## wherein the naphthyl ring is unsubstituted or substituted with one, two or three substitutents independently selected from lower alkyl, trifluoromethyl, alkoxy and halo. Alternatively, R.sub.6 is as defined above and R.sub.7 is R.sub.12 OC(O)-- wherein R.sub.12 is benzyl; or R.sub.6 and R.sub.7 taken together with the nitrogen atom to which they are bonded form ##STR5## wherein R.sub.
Type:
Grant
Filed:
May 30, 1997
Date of Patent:
August 3, 1999
Assignee:
Abbott Laboratories
Inventors:
Anthony R. Haight, Timothy L. Stuk, Jerome A. Menzia
Abstract: A compound of the formula: ##STR1## is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
Type:
Grant
Filed:
November 21, 1996
Date of Patent:
June 22, 1999
Assignee:
Abbott Laboratories
Inventors:
Hing Leung Sham, Daniel W. Norbeck, Xiaoqi Chen, David A. Betebenner
Abstract: A compound of the formula: ##STR1## is disclosed as a retroviral protease inhibitor compound. Also disclosed are methods and compositions for inhibiting an HIV infection.
Type:
Grant
Filed:
September 24, 1996
Date of Patent:
May 18, 1999
Assignee:
Abbott Laboratories
Inventors:
Xiaoqi Chen, Brian E. Green, Dale J. Kempf, Lin Li, Daniel W. Norbeck, Hing L. Sham
Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.
Type:
Grant
Filed:
May 4, 1995
Date of Patent:
March 2, 1999
Assignee:
Abbott Laboratories
Inventors:
Laman A. Al-Razzak, Kennan C. Marsh, Dilip Kaul, Lourdes P. Manning
Abstract: A retroviral protease inhibiting compound of the formula A--X--B is disclosed. Also disclosed are a composition and method for inhibiting a retroviral protease and for treating an HIV infection. Also disclosed are processes and intermediates useful for the preparation of the retroviral protease inhibitors.
Type:
Grant
Filed:
March 24, 1995
Date of Patent:
November 17, 1998
Assignee:
Abbott Laboratories
Inventors:
Daniel W. Norbeck, Lynn M. Codacovi, Steven J. Wittenberger
Abstract: The present invention provides a compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof, which are useful for inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras or inhibiting de novo squalene production resulting in the inhibition of cholesterol biosynthesis, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.
Type:
Grant
Filed:
April 11, 1996
Date of Patent:
November 3, 1998
Assignee:
Abbott Laboratories
Inventors:
David L Arendsen, William R. Baker, Stephen A Fakhoury, Anthony K. L. Fung, David S. Garvey, William J. McClellan, Stephen J. O'Connor, Rajnandan N. Prasad, Todd W. Rockway, Saul H. Rosenberg, Herman H. Stein, Wang Shen, David M. Stout, Gerard M. Sullivan, David J. Augeri
Abstract: Intermediates and processes are disclosed which are useful for the preparation of a substantially pure compound of the formula: ##STR1## wherein R.sub.6 and R.sub.7 are each hydrogen or R.sub.6 and R.sub.7 are independently selected from ##STR2## wherein R.sub.a and R.sub.b are independently selected from hydrogen, loweralkyl and phenyl and R.sub.c, R.sub.d and R.sub.e are independently selected from hydrogen, loweralkyl, trifluoromethyl, alkoxy, halo and phenyl; and ##STR3## wherein the naphthyl ring is unsubstituted or substituted with one, two or three substituents independently selected from loweralkyl, trifluoromethyl, alkoxy and halo; orR.sub.6 is as defined above and R.sub.7 is R.sub.7a OC(O)-- wherein R.sub.7a is loweralkyl or benzyl; orR.sub.6 and R.sub.7 taken together with the nitrogen atom to which they are bonded are ##STR4## wherein R.sub.f, R.sub.g, R.sub.h and R.sub.i are independently selected from hydrogen, loweralkyl, alkoxy, halogen and trifluoromethyl and R.sub.
Abstract: The present invention provides a compound of the formula ##STR1## which inhibit squalene synthetase and cholesterol biosynthesis and are useful in the treatment of e.g., hyperlipidaemia, atherosclerosis, or fungal infections, processes for the preparation of the compounds of the invention, intermediates useful in these processes, and pharmaceutical compositions containing the compounds.
Type:
Grant
Filed:
April 29, 1996
Date of Patent:
July 21, 1998
Assignee:
Abbott Laboratories
Inventors:
William R. Baker, Saul H. Rosenberg, Anthony K. L. Fung, Todd W. Rockway, Stephen A. Fakhoury, David S. Garvey, B. Gregory Donner, Stephen J. O'Connor, Rajnandan N. Prasad, Wang Shen, David M. Stout, Gerard M. Sullivan
Abstract: The present invention relates to a process for the preparation of cabonate compounds useful for the preparation of compounds which are human immunodeficiency virus (HIV) protease inhibitors.The compounds have formula I: ##STR1## wherein R.sup.9 is hydrogen or lower alkyl, and the thiazolyl ring can be unsubituted or substituted with a lower alkyl group.
Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
Type:
Grant
Filed:
May 30, 1995
Date of Patent:
June 16, 1998
Assignee:
Abbott Laboratories
Inventors:
Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen
Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
March 24, 1998
Assignee:
Abbott Laboratories
Inventors:
Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen
Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.
Type:
Grant
Filed:
May 4, 1995
Date of Patent:
March 10, 1998
Assignee:
Abbott Laboratories
Inventors:
Laman A. Al-Razzak, Kennan C. Marsh, Dilip Kaul, Lourdes P. Manning
Abstract: A process for the preparation of 5-hydroxymethylthiazole comprises reacting a compound of the formula, ##STR1## with a carboxylic acid salt (optimally in the presence of a quaternary ammonium salt) and hydrolyzing the resulting ester. Subsequent dechlorination gives 5-hydroxymethylthiazole.
Type:
Grant
Filed:
May 22, 1996
Date of Patent:
January 27, 1998
Assignee:
Abbott Laboratories
Inventors:
M. Robert Leanna, Howard E. Morton, Michael S. Allen
Abstract: The present invention relates to compounds of the formula I ##STR1## wherein A, Y, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, l, m and the corresponding radicals labeled with * are defined as stated in the description, a process for their preparation and their use for the inhibition of retroviral proteases.
Type:
Grant
Filed:
July 11, 1994
Date of Patent:
January 27, 1998
Assignee:
Abbott Laboratories
Inventors:
Karl-Heinz Budt, Bernd Stowasser, Dieter Ruppert, Christoph Meichsner, Arnold Paessens, Jutta Hansen, Jochen Knolle